

ASX Release

NOVITA HEALTHCARE STRENGTHENS BOARD FOR GROWTH SUE MACLEMAN APPOINTED NEW CHAIR

The Directors of Novita Healthcare Limited (ASX: NHL), (“Novita” or the “Company”) are pleased to announce the appointment of Sue MacLeman as Chair (and Non-Executive Director) of the Company with effect 6th September 2018.

Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive with senior roles in corporate, medical, commercial and business development.

Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently Chair, Anantara Lifesciences Ltd, Chair Elect and Non-Executive Director of MTPConnect (Medical Technology and Pharmaceuticals Industry Innovation Growth Centre MTPII-GC Ltd), Non-Executive Director Oventus Medical Ltd and Veski. Sue is also appointed to a number of academic and government advisory committees.

Her broad commercial experience is underpinned by graduate qualifications in pharmacy and post graduate qualifications in commercial law, corporate governance, business administration and marketing.

Commenting on the appointment, Managing Director Glenn Smith said, “The Board and I are delighted to welcome Sue to the role of Board Chair. Sue has been a pioneer in many ways in the technology and medical sector over numerous decades. Her proven experience in global strategy, marketing and business development will help guide Novita Healthcare to deliver on its promise to be a global health technology company. We all look forward to working with Sue as Chair for many years to come.”

On joining the board, Ms MacLeman remarked, “I am delighted to be joining Novita Healthcare at such an exciting time. TALI Train is gaining interest with parents, teachers and with the medical profession. It has the potential to make a difference to children with attention difficulties globally and this should also resonate with investors.”

The Board wishes to thank Mark Simari for his leadership as Chairman during the past months with Mr Simari remaining a Non-Executive Director of the Company.

As a sign-on incentive for Sue to join the Board as Chair, the Company has invited her to apply for the issue of 6.8 million options on the same terms and conditions as the Director Options issued and advised to the market on 21 November 2017¹.

ABOUT NOVITA HEALTHCARE

Novita Healthcare is an emerging health sector technology company targeting ATTENTION in children through its breakthrough technology TALI. TALI Train uses proprietary algorithms inside a game-based learning application to improve core attention skills in early childhood (www.talihealth.com).

CONTACTS

Glenn Smith

Managing Director

Novita Healthcare Limited

P:1300 082 013

E: novita@novitahealthcare.com.au



¹ At the Annual General Meeting held on 30 October 2017 the Shareholders approved the issue of Director Options to three of the non-executive directors at the time. The details of the terms of the Director Options were shown in the Notice of Meeting of 28 September 2017. On 21 November 2017 the Company issued of this tranche of Director Options and lodged an Appendix 3B summarising the terms. The 6.9 million Director Options offered to Ms MacLeman will, if she accepts the invitation, entitle the holder after 21 November 2020 to be issued with one share for each option held upon payment of 3.0¢ per share on condition that for any period of 20 consecutive days commencing after the end of 21 November 2020 the share price of Novita Healthcare Limited fully paid ordinary shares listed on the Australian Stock Exchange is a minimum of 7.5¢ per share. The Options have a term of 5 years from 21 November 2017 and expire on 21 November 2022. All other terms identical with the Director Options issued on 21 November 2017.